Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress
15 Mai 2023 - 7:00AM
Business Wire
IPH6501, a first-in-class tetra-specific
antibody-based natural killer cell engager therapeutic developed
for the treatment of B-cell non-Hodgkin's lymphomas, selected for
oral presentation
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced that new
preclinical data on its IPH6501 tetra-specific ANKET®
(Antibody-based Natural Killer cell
Engager Therapeutics) have been selected for oral
presentation at the European Hematology Association (EHA) 2023
congress, being held 8 to 15 June 2023 in Frankfurt, Germany.
ANKET® is Innate’s proprietary platform for developing
next-generation, multi-specific natural killer (NK) cell engagers
to treat certain types of cancer. This fit-for-purpose technology
is creating an entirely new class of molecules to induce synthetic
immunity against cancer. Innate’s latest innovation, the
tetra-specific ANKET®, is the first NK cell engager technology to
engage activating receptors (NKp46 and CD16), a tumor antigen and
the interleukin-2 receptor (via a non-alpha IL-2 variant, IL-2v)
via a single molecule. By providing proliferation and activation
signals targeted to NK cells, tetra-specific ANKET® leverages the
advantages of harnessing NK cell effector functions against cancer
cells.
IPH6501, the first tetra-specific ANKET®, continues toward a
Phase 1 clinical trial in 2023.
Presentation details
Presentation: S258
Title: IPH6501 is a first-in-class
tetraspecific antibody-based natural killer cell engager
therapeutic developed for the treatment of B-cell non-Hodgkin's
lymphomas
Session: s425 Gene therapy and
immunotherapy - Biology & translational research
Date and time: 10/06/2023, 11:30 -
12:45
Location: Fantasie
Speaker: Olivier Demaria, PhD, R&D
Director, Science Leader at Innate Pharma
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through therapeutic antibodies and its ANKET®
(Antibody-based NK cell Engager
Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, as well as ANKET® multi-specific NK
cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on Twitter and LinkedIn.
Information about Innate Pharma shares
ISIN code Ticker
code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2022,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230514005036/en/
Investors Innate
Pharma Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024